(By Balachander) Nu Skin Enterprises Inc. (NYSE: NUS) forecast higher earnings and revenue for 2013 and the provider of anti-aging products agreed to acquire NOX Technologies Inc., a biodiagnostic company, for $12.5 million.
The company expects earnings per share (EPS) in the range of $3.70 to $3.85 on revenue between $2.25 billion and $2.30 billion. This represents EPS growth of 10 percent to 15 percent and revenue increase of 7 percent to 9 percent over 2012.
Wall Street analysts, on average, expect EPS of $3.85 on revenue of $2.28 billion.
The company expects "strong growth" in its sales leaders and consumer base, healthy trends in all of its regions, and a record launch of its new ageLOC weight management system in 2013.
Meanwhile, Nu Skin said the purchase of NOX will strengthen its long-term pipeline of scientifically validated anti-aging services.
Malvern, Pennsylvania-based NOX, established in 2003, is focused on the identification, characterization and detection of cell surface proteins relating to aging. arNOX, an age-related protein identified by NOX Technologies, is found on the cell surface and is capable of superoxide generation, a relevant aspect of the aging process.
The deal is expected to be completed before the end of 2012.
NUS shares, which have been trading in the 52-week range of $36.20 to $62.01, closed at $46.11 on Tuesday.